Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Bioengineer receives $1.4M grant to create nanoparticle system to shore up arterial walls

A UT Arlington bioengineer has received a four-year, $1.4 million National Institutes of Health grant to create a nanoparticle system to shore up arterial walls following angioplasty and stenting procedures to treat coronary arterial disease.

5 Feb 2014

Scientists engineered microchip coated with blood vessel cells to study cardiovascular nanomedicine

Designing nanomedicine to combat diseases is a hot area of scientific research, primarily for treating cancer, but very little is known in the context of atherosclerotic disease.

5 Feb 2014

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy in response to motor symptoms.

5 Feb 2014

New study reveals way to combat drug-resistant tumors

Cancer drugs that recruit antibodies from the body's own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.

31 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014.

28 Jan 2014

Remarkable properties of new, porous material could lead to advances in microscopic sponging

The sponges of the future will do more than clean house. Picture this, for example: Doctors use a tiny sponge to soak up a drug and deliver it directly to a tumor. Chemists at a manufacturing plant use another to trap and store unwanted gases.

28 Jan 2014

Silk and diamonds could provide novel technique for biological imaging, drug delivery

Silk and diamonds aren't just for ties and jewelry anymore. They're ingredients for a new kind of tiny glowing particle that could provide doctors and researchers with a novel technique for biological imaging and drug delivery.

28 Jan 2014

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.

23 Jan 2014

New injectable material delivers drug therapies and sensor technology to targeted areas in human body

A new injectable material designed to deliver drug therapies and sensor technology to targeted areas within the human body is being developed by a Texas A&M University biomedical engineer who says the system can lock its payload in place and control how it is released.

23 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

Research identifies new way for slow release drugs

Reservoirs of pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for slow, concentrated delivery of drug treatments, according to new research published in ACS Macro Letters.

15 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

Researchers at the Winship Cancer Institute of Emory University have discovered a more effective drug delivery system using nanotechnology that could one day significantly affect cancer prevention.

8 Jan 2014

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.

8 Jan 2014

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

7 Jan 2014

Ossianix forms strategic research partnership with Lundbeck

Ossianix, Inc. today announced a strategic research collaboration with Lundbeck A/S. This collaboration follows a previous investment in 2012. The collaboration uses Ossianix's innovative single domain antibody platform based on the shark VNAR structure and will focus on two projects.

6 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

Rainbow Coral to hunt for new innovations, potential partnerships at Biotech Showcase

Executive leadership from Rainbow Coral Corp., a fast-rising biotechnology company, will scout for new innovations and potential partnerships this month at the sixth annual Biotech Showcase in San Francisco.

3 Jan 2014

Smiths Medical gets FDA clearance to market CADD-Solis system with PIB and PCA delivery in the US

Smiths Medical, a leading global medical device manufacturer, announced today it has received FDA 510(k) clearance to market its CADD-Solis pain management system version 3.0 with Programmed Intermittent Bolus and Patient Controlled Analgesics delivery in the United States. The new customizable, infusion system will help healthcare providers overcome challenges in maintaining effective epidural analgesia during labor and delivery or with post-operative pain management.

2 Jan 2014

Drug Delivery News and Research

Further Reading

Bioengineer receives $1.4M grant to create nanoparticle system to shore up arterial walls

Scientists engineered microchip coated with blood vessel cells to study cardiovascular nanomedicine

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

New study reveals way to combat drug-resistant tumors

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Remarkable properties of new, porous material could lead to advances in microscopic sponging

Silk and diamonds could provide novel technique for biological imaging, drug delivery

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

New injectable material delivers drug therapies and sensor technology to targeted areas in human body

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Research identifies new way for slow release drugs

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

Research opens door to new direction of PAH treatment

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Ossianix forms strategic research partnership with Lundbeck

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Rainbow Coral to hunt for new innovations, potential partnerships at Biotech Showcase

Smiths Medical gets FDA clearance to market CADD-Solis system with PIB and PCA delivery in the US

Pharmaron’s drug conjugates platform from idea to XDC eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo